GBS toxin receptor antibodies

Details GBS toxin receptor antibodies GBS toxin receptor antibodies

2004-04-12

2008-08-12

Li, Ruixiang (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C530S387100, C530S388100, C530S387300

Reexamination Certificate

active

07410640

ABSTRACT:
A novel GBS toxin receptor and methods for its preparation and use are provided. GBS toxin receptor polynucleotides and polypeptides and antibodies to GBS toxin receptor are provided, as well as detection, screening, and therapeutic methods and pharmaceutical compositions involving such polynucleotides, polypeptides and antibodies.

REFERENCES:
patent: 4242326 (1980-12-01), Sugawara et al.
patent: 5010062 (1991-04-01), Hellerqvist
patent: 5811403 (1998-09-01), Hellerqvist
patent: 5858991 (1999-01-01), Hellerqvist et al.
patent: 5939396 (1999-08-01), Hellerqvist
patent: WO 91/04048 (1991-04-01), None
patent: WO 97/41844 (1997-11-01), None
patent: WO 98/14603 (1998-04-01), None
patent: WO 98/32448 (1998-07-01), None
patent: WO 98/32452 (1998-07-01), None
patent: WO 98/32453 (1998-07-01), None
patent: WO 98/40487 (1998-09-01), None
Devore et al., “Phase I Study of the Antineovascularization Drug CM101,”Clinical Cancer Research, vol. 3, pp. 365-372 (1997).
Fu, et al., “Expressional Cloning of CM101 Receptor Gene from Mammalian Cells,”Proceedings of the American Association of Cancer Research, Abstract 3677, vol. 40, p. 557 (1999).
Gearing, et al., “Expression Cloning of a Receptor for Human Granulocyte-Macrophage Colony-Stimulating Factor,”The EMBO Journal, vol. 8, No. 12, pp. 3667-3676 (1989).
Hellerqvist et al., “Anti-Tumor Effects of GBS Toxin are Caused by Induction of a Targeted Inflammatory Reaction,”Angiogenesis: Molecular Biology, Clinical Aspects, Edited by Maragoudakis et al., Plenum Press, New York, pp. 265-269 (1994).
Hellerqvist et al., “Antitumor Effects of GBS Toxin: A Polysaccharide Exotoxin From Group B β-HemolyticStreptococcus,”J. Cancer Res. Clin. Oncol., vol. 120, pp. 63-70 (1993).
Hellerqvist et al., “Molecular Basis for Group B β-Hemolytic Streptococcal Disease,”Proc. Natl. Acad. Sci. USA, vol. 84, pp. 51-55 (1987).
Hellerqvist et al., “Preliminary Results of a Phase I Trial of CM101 in Cancer Patients,”J. Cellular Biochemistry, Suppl. 19B, p. 26 (1995).
Hellerqvist et al., “Studies on Group B β-HemolyticStreptococcus. I. Isolation and Partial Characterization of an Extracellular Toxin,”Pediatr. Res., vol. 15. pp. 892-898 (1981).
Hillier, et al., “zr59d01.rl Soares NhHMPu S1Homo sapienscDNA clone 667681 5′ Similar to Tr:G507415 G507415 Brain Specific Na+-Dependent Inorganic Phosphate Cotransporter,” Database EMBL—EMEST20 'Online!, Entry HS1173506, Acc. No. AA258513 (Mar. 19, 1997).
Kovacs et al., “Fibrogenic Cytokines and Connective Tissue Production,”The FASEB Journal, vol. 8, pp. 854-861 (1994).
Norrby, “Angiogenesis: New Aspects Relating to Its Initiation and Control,”APMIS, vol. 105, pp. 417-437 (1997).
Polverini, “The Pathophysiology of Angiogenesis,”Crit. Rev. Oral. Biol. Med., vol. 6, No. 3, pp. 230-247 (1995).
Quinn, et al., “CM101, A Polysaccharide Antitumor Agent, Does Not Inhibit Wound Healing in Murine Models,”J. Cancer Res. Clin. Oncol., vol. 121, pp. 253-256 (1995).
Thurman, et al., “Actue Inflammatory Changes in Subcutaneous Microtumors in the Ears of Mice Induced by Intravenous CM101 (GBS Toxin),”J. Cancer Res. Clin. Oncol., vol. 122, pp. 549-553 (1996).
Wamil, et al., “Soluble E-Selectin in Cancer Patients as a Maker of the Therapeutic Efficacy of CM101, a Tumor-Inhibiting Anti-Neovascularization Agent, Elevated in Phase I Clinical Trail,”J. Cancer Res. Clin. Oncol., vol. 123, pp. 173-179 (1997).

Affiliated with

Also associated with

Rating

GBS toxin receptor antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with GBS toxin receptor antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and GBS toxin receptor antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4019878